Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700659 · ClinicalTrials.gov registry record
The Cxbladder Monitoring Study
A clinical trial of Urothelial Carcinoma, sponsored by Pacific Edge Limited.
- Completed
- Registry status
- 803
- Enrollment target
- 11
- Study locations
NCT02700659: Completed study of Urothelial Carcinoma, sponsored by Pacific Edge Limited.
NCT02700659 is a study of Urothelial Carcinoma that has completed, run by Pacific Edge Limited. The registered enrollment target is 803 participants, above the 230-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (249% higher). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02700659, a study of Urothelial Carcinoma, has completed, sponsored by Pacific Edge Limited.
- COMPLETED
- Registry status
- 803 participants
- Enrollment target
- 11
- Study locations
Study Summary
The aim of this trial is to determine the performance characteristics of the Cxbladder test for the detection of recurrent urothelial carcinoma (UC) in patients with a recent history of urinary tract UC, who have been treated according to standard practice and are undergoing routine investigative cystoscopy. The gold standard for determination of clinical truth is cystoscopy, plus any follow up investigations relating to the current visit.
Primary Outcome
The Cxbladder test results will be compared to that of cystoscopy, which is the gold standard method for diagnosing urothelial cancer; the true positive and true negative rates will be measured, along with the false positive and false negative rates of the test. The results will be reported as sensitivity and specificity of the Cxbladder test for detecting urothelial cancer in patients with recurrent disease.
Conditions Studied
Interventions
- OTHER Cxbladder
Study Locations (11)
New York
- Premier Medical Group of the Hudson Valley - Kingston
- Weill Cornell Medical College, Department of Urology - New York
- Premier Medical Group of the Hudson Valley - New York
- Premier Medical Group of the Hudson Valley - Newburgh
Alabama
- Urology Centers of Alabama - Homewood
Connecticut
- Urology Center of Grove Hill, One Lake Street - New Britain
Florida
- Florida Urology Associates - Orlando
Idaho
- Idaho Urologic Institute - Meridian
New Jersey
- Delaware Valley Urology, LLC - New Jersey
Pennsylvania
- Penn State Hershey Medical Center and College of Medicine - Hershey
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2013-02-04 |
| Est. Completion | 2016-09-23 |
What the finished NCT02700659 record still lists
NCT02700659 is an observational study that tracks outcomes without assigning an intervention. The registered 803 participants enrollment target is mid-sized for trials with a published cap, above the 230-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (249% higher).
The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cxbladder is the first listed.
NCT02700659 lists 11 locations in 8 states (New York, Alabama, Connecticut).
Frequently Asked Questions
What is clinical trial NCT02700659 about?
NCT02700659 is a clinical study titled "The Cxbladder Monitoring Study". The aim of this trial is to determine the performance characteristics of the Cxbladder test for the detection of recurrent urothelial carcinoma (UC) in patients with a recent history of urinary tract UC, who have been treated according to standard practice and are undergoing routine investigative cy...
What is the current status of trial NCT02700659?
This trial is currently completed. The enrollment target is 803 participants. The study started on 2013-02-04. Estimated completion is 2016-09-23.
What conditions does trial NCT02700659 study?
This clinical trial studies the following conditions: Urothelial Carcinoma.
What interventions are being tested in trial NCT02700659?
The interventions under investigation include: Cxbladder (OTHER).
Who is sponsoring clinical trial NCT02700659?
This trial is sponsored by Pacific Edge Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02700659 being conducted?
This trial has 11 study locations across Alabama, Connecticut, Florida, Idaho, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02700659's enrollment target sits among peer trials
803 8th of 85 higher than 78 of 85 other Urothelial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI